



PREVALENCE of **LUNG cancer** in SWITZERLAND

Figure 1. Observed and projected number of patients having been diagnosed with malignant cancer of the lung and bronchus by index year and years since diagnosis.



**Table 1. Malignant cancer of the lung and bronchus (ICD-10 C33-34).
Limited-duration prevalence in Switzerland by sex, age and year.**

		Limited-duration prevalence ²															
		Men								Women							
		2000		2005		2010		2015		2000		2005		2010		2015	
Age ³	Time since diagnosis [years]	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹
0-49	up to 2	174	7.2	115	4.7	98	3.9	120	4.7	86	3.6	106	4.4	115	4.6	162	6.5
	up to 5	224	9.2	178	7.2	149	5.9	172	6.7	149	6.3	159	6.6	166	6.7	227	9.1
	up to 10	247	10.2	207	8.4	186	7.3	195	7.5	191	8.0	192	8.0	213	8.6	253	10.1
	2 to 5	49	2.0	63	2.6	51	2.0	52	2.0	63	2.7	53	2.2	52	2.1	65	2.6
	5 to 10	24	1.0	30	1.2	37	1.4	23	0.9	43	1.8	33	1.4	47	1.9	25	1.0
50-59	up to 2	413	88.2	454	92.9	374	70.5	381	63.0	258	55.3	291	59.6	295	56.3	392	66.4
	up to 5	591	126.3	629	128.9	542	102.0	557	92.1	324	69.4	461	94.4	441	84.2	575	97.3
	up to 10	714	152.6	752	154.0	687	129.3	697	115.3	408	87.3	560	114.7	553	105.4	680	115.2
	2 to 5	178	38.1	175	35.9	167	31.5	176	29.1	66	14.1	170	34.8	146	27.8	183	30.9
	5 to 10	123	26.3	123	25.2	145	27.3	141	23.3	84	17.9	99	20.3	111	21.3	105	17.8
60-69	up to 2	702	222.3	651	179.3	792	189.3	795	178.4	272	77.5	383	98.7	526	120.2	650	141.4
	up to 5	1035	327.7	980	270.1	1189	283.9	1184	265.8	402	114.5	624	161.0	847	193.5	1013	220.4
	up to 10	1306	413.5	1248	343.9	1529	365.2	1515	340.1	483	137.8	750	193.4	1101	251.6	1328	288.8
	2 to 5	333	105.5	329	90.7	396	94.6	389	87.4	130	37.1	241	62.3	320	73.2	363	79.0
	5 to 10	271	85.8	268	73.8	340	81.2	331	74.3	82	23.3	126	32.4	254	58.1	314	68.4
70-79	up to 2	613	292.0	736	322.9	644	256.8	697	238.2	288	98.3	348	116.0	407	131.0	490	142.9
	up to 5	975	464.4	1125	493.7	999	398.5	1087	371.4	411	140.0	530	176.5	621	199.7	730	213.0
	up to 10	1217	579.9	1499	657.4	1330	530.3	1427	487.4	556	189.5	651	216.7	828	266.6	984	286.9
	2 to 5	362	172.4	389	170.8	355	141.7	390	133.2	123	41.8	182	60.5	214	68.8	241	70.1
	5 to 10	243	115.6	373	163.7	331	131.8	340	116.0	145	49.5	121	40.2	208	66.9	253	73.8
80+	up to 2	171	178.1	247	218.1	297	225.9	289	190.2	88	44.6	124	55.8	179	73.0	206	78.3
	up to 5	249	259.0	382	336.8	424	323.0	412	271.3	135	68.3	181	81.1	266	108.4	315	119.8
	up to 10	332	345.3	511	451.2	605	460.6	596	393.1	180	90.9	268	120.1	352	143.4	428	162.5
	2 to 5	78	80.9	135	118.8	127	97.1	123	81.1	47	23.7	56	25.3	87	35.5	109	41.5
	5 to 10	83	86.3	129	114.3	181	137.6	185	121.8	45	22.6	87	39.0	86	35.0	112	42.7
All ages	up to 2	2074	58.9	2202	60.3	2206	56.9	2281	56.0	993	26.9	1252	32.9	1522	38.1	1900	45.6
	up to 5	3074	87.3	3294	90.2	3303	85.2	3412	83.8	1421	38.6	1955	51.3	2341	58.6	2861	68.7
	up to 10	3817	108.5	4217	115.4	4336	111.9	4430	108.8	1819	49.3	2420	63.6	3048	76.3	3672	88.2
	2 to 5	1000	28.4	1091	29.9	1097	28.3	1130	27.8	428	11.6	702	18.4	819	20.5	961	23.1
	5 to 10	743	21.1	923	25.3	1033	26.7	1019	25.0	398	10.8	465	12.2	707	17.7	810	19.5

¹ Proportion per 100'000

² Estimated with Counting/Projection-Method (see chapter B and C in document "Prevalence estimation methods")

³ Age at index date

**Table 2. Malignant cancer of the lung and bronchus (ICD-10 C33-34).
Complete prevalence in Switzerland by sex and year.**

		Complete prevalence ²															
		Men								Women							
		2000		2005		2010		2015		2000		2005		2010		2015	
Age ³	Time since diagnosis [years]	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹
All ages	more than 10	898	25.5	867	23.7	938	24.2	1069	26.2	329	8.9	455	12.0	605	15.2	872	20.9
	unlimited ⁴	4716	134.0	5084	139.2	5274	136.1	5499	135.0	2148	58.3	2875	75.5	3653	91.5	4543	109.1

¹ Proportion per 100'000

² Estimated with Age-Period-Cohort model PIAMOD (see chapter D in document "Prevalence estimation methods")

³ Age at index date

⁴ Modelled prevalence is potentially underestimated as compared with counted prevalence in Tab. 1. The modelled 5-year limited duration prevalence for 2000 - 2010 in men was 11% smaller on average, and in women 13% (see chapter D 4.2. in document "Prevalence estimation methods"). The complete prevalence was estimated by taking the sum of counted limited duration prevalences (0-2, 2-5, 5-10) and the modelled 10+ years prevalence.

May 2014

Contact: Matthias Lorez, PhD MAS
Foundation National Institute for Cancer Epidemiology and Registration (NICER)
c/o Universität Zürich
Seilergraben 49
CH-8001 Zürich
ml@nicer.org